Machine Learning used in real-world analysis of COVID-19 pharmacotherapy
- Real-world data generated from clinical practice can be used to analyse the real-world evidence (RWE) of COVID-19 pharmacotherapy and validate the results of randomised clinical trials (RCTs)
- 5244 and 1312 COVID-19 hospital admissions – dated between January 2020 and January 2021 from 10 health departments, were used respectively for training and validation of separate treatment-effect models for remdesivir, corticosteroids, tocilizumab, lopinavir-ritonavir, azithromycin and chloroquine/hydroxychloroquine
- Machine Learning (ML) methods are suitable tools toward RWE analysis of COVID-19 pharmacotherapies. Results obtained reproduce published results on RWE and validate the results from RCTs
Click here to learn more.
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.